From discovery and preclinical research to manufacturing, regulatory strategy, CMC and investment, the 5th iPSC Drug Development Summit is your most comprehensive platform to engage with cross-functional stakeholders advancing iPSC-derived therapies toward the clinic and beyond.
This meeting uniquely brings together experts from across the iPSC therapy value chain spanning R&D, process development, regulatory affairs, and business development to openly discuss shared challenges and solutions for genetically stable, scalable, and clinically efficacious iPSC-derived therapies. With leading voices from Astellas Pharma, Sana Biotechnology, BlueRock Therapeutics, Novo Nordisk, GC Therapeutics, and Kenai Therapeutics, this is your opportunity to align on technical priorities and forge lasting, strategic partnerships across therapeutic areas.
Experts Need Your Help With:
Improving consistency and scalability of iPSC-derived cell manufacturing to meet GMP and commercial readiness standards
Enhancing genetic engineering tools to enable efficient, stable, and safe modification of iPSC lines across diverse therapeutic programs
Developing robust differentiation protocols that reliably yield high-purity, functional cell types for specific disease indications
Refining QC and release testing strategies to ensure regulatory compliance and predict in vivo performance of iPSC-derived products
Streamlining cryopreservation and cell storage solutions that maintain cell viability, identity, and functionality at scale
Why Partner With The Summit?
Targeted Exposure to Decision-Makers: Engage directly with senior leaders and technical experts from leading iPSC drug developers actively seeking solutions to advance their programs toward the clinic
Position Your Brand as a Key Enabler: Showcase your capabilities and thought leadership at the industry’s longest-standing iPSC-dedicated forum, where your solutions can directly address pressing CMC, preclinical, and manufacturing needs
Accelerate Commercial Opportunities: Gain insider insights into current project bottlenecks and pipeline priorities to better tailor your innovations and build high-value, long-term partnerships
Who Will You Meet?
